
|Videos|July 14, 2022
Dr. Barata stresses significance of tumor sequencing in urothelial carcinoma
Author(s)Urology Times staff
“The real-world data suggest that the use of tumor sequencing is definitely suboptimal,” says Pedro C. Barata, MD, MSc.
Advertisement
Pedro C. Barata, MD, MSc, an associate professor of Medicine in Hematology and Medical Oncology at the Tulane University School of Medicine, discusses the importance of tumor sequencing to the implementation of precision medicine for patients with urothelial carcinoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA approves cefepime and zidebactam for complicated UTI
4
FDA updates in urology: May 2026
5










